Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance
Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance
复制标题
DOI：
10.1097/qad.0b013e328346269f
复制
发表时间：
2011-05-15
期刊：
影响因子：
3.8
通讯作者：
Ekstrand, Maria L.
中科院分区：
文献类型：
--
作者：
Neogi, Ujjwal;Shet, Anita;Ekstrand, Maria L.
对 552 名印度患者队列中的 92 名 HIV-1C 感染患者进行了依曲韦林基因型耐药率的评估，这些患者接受奈韦拉平和依非韦伦治疗方案失败。总体而言，使用 Tibotec 加权评分确定的依曲韦林交叉耐药率为 41%（31.5% 中度耐药，9.8% 完全耐药）。最常见的非核苷逆转录酶抑制剂相关突变包括 Y181 (35.9%)、K101 (20.7%)、G190 (17.4%) 和 V108 (15.2%)。与易感组相比，耐药组表现出更高的病毒载量（P = 0.01）和更长的抗逆转录病毒治疗持续时间（P = 0.03）。
Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian patients. Overall, prevalence of etravirine cross-resistance identified using the Tibotec Weighted Score was 41% (31.5% intermediately-resistant and 9.8% fully-resistant). The most frequently described nonnucleoside reverse transcriptase inhibitor-associated mutations included Y181 (35.9%), K101 (20.7%), G190 (17.4%), and V108 (15.2%). The resistant group demonstrated higher viral load (P = 0.01) and longer duration of antiretroviral treatment (P = 0.03) compared with the susceptible group.